Tourdot, Sophie, Bloem, Karin, Champion, Lysie, de Groot, Anne, Ducret, Axel, Fraser, Sasha, Garide, Patrick, Grudzinska-Goebel, Joanna, Gutknecht, Michael, Hickling, Timothy, Horling, Frank, Ichetovkin, Marina, Johnson, Alison, Jyamubandi, Issa, Karle, Anette, Kromminga, Arno, Kurtulmus, Ebru Aydin, Loeff, Floris, Maillere, Bernard, Michaut, Lydia, Minelli, Francesca, Nielsen, Morten, Nayak, Vivek, Nelson, Robert, Pallardy, Marc, Pattyn, Sofie, Pedras-Vasconelos, Joao, Pepermans, Elise, Poyau, Alain, Reichel, Matthias, Rosenberg, Amy, Sauna, Zuben, Saxena, Manisha, Smith, Noel, Snoeck, Veerle, Thoo, Lester, Tovey, Michael, Verthelyi, Daniela, Wuttke, Rene, Yerly, Daniel and Kramer, Daniel (2025) Proceedings of the 15th European Immunogenicity Platform Open Symposium on Immunogenicity of Biopharmaceuticals. mAbs, 16 (1). ISSN https://doi.org/10.1080/19420862.2024.2324801

Abstract

This year, the European Immunogenicity Platform celebrated the 15th edition of its Open Symposium on Immunogenicity of Biopharmaceuticals and its associated one-day workshop. The meeting attracted experts and newcomers across industry, regulatory agencies and academia, who actively participated in 3 days of discussion on risk assessment, monitoring and mitigation of unwanted immunogenicity of biologics. Besides oral presentations, poster sessions were held to maximize scientific exchange and networking opportunities. Here, we report the discussions that took place April 22-24 in Lisbon.

Item Type:	Article
Keywords:	immunogenicity, ADA, clinical relevance, risk assessment, anti-drug antibodies
Date Deposited:	06 May 2025 00:45
Last Modified:	06 May 2025 00:45
URI:	https://oak.novartis.com/id/eprint/56594